Posted by Michael Wonder on 28 Nov 2017
EMA accepts Titan Pharmaceuticals' marketing authorisation application for Probuphine
27 November 2017 - Acceptance marks beginning of regulatory review process for opioid use disorder treatment with Probuphine in Europe.
Titan Pharmaceuticals today announced that the EMA has accepted for review its marketing authorisation application for Probuphine.
The acceptance marks the beginning of the EMA's regulatory review process for Probuphine for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.
